White Paper

Rare Disease: Beginning With The Patient In Mind

GettyImages-1027587952-nurse-doctor-patient-comfort

Patient centricity is top of mind in drug development today – and rightly so. The rapid evolution of the industry over the past year alone has brightened that spotlight more than ever, making patient centricity imperative. The question becomes: How do we expand perspectives from a myopic scientific lens to apply holistic real-world considerations to drug development strategy and trial design that truly have the patient in mind? Specifically, how do we accommodate the true real-world patient journey in a population that is unlike any other – the rare disease patient?

Involving patients in the drug development process provides context for benefit-risk assessment as well as aids in the development of new assessment tools, study endpoints, and risk communications.1 Creating genuinely patient-centric drug development programs takes careful consideration and intention; in some cases, it requires an additional financial investment. But this effort can result in generating better outcomes for all stakeholders and reflect the ultimate goal of research and development – an improvement in the lives of more patients.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: